WO2000060066A8 - Protein-protein from s. cerevisiae and methods of using same - Google Patents

Protein-protein from s. cerevisiae and methods of using same

Info

Publication number
WO2000060066A8
WO2000060066A8 PCT/US2000/008399 US0008399W WO0060066A8 WO 2000060066 A8 WO2000060066 A8 WO 2000060066A8 US 0008399 W US0008399 W US 0008399W WO 0060066 A8 WO0060066 A8 WO 0060066A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
complexes
same
polypeptide
protein
Prior art date
Application number
PCT/US2000/008399
Other languages
French (fr)
Other versions
WO2000060066A1 (en
Inventor
Loic Giot
Traci A Mansfield
Original Assignee
Curagen Corp
Loic Giot
Traci A Mansfield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Loic Giot, Traci A Mansfield filed Critical Curagen Corp
Priority to EP00921513A priority Critical patent/EP1165772A1/en
Priority to AU41820/00A priority patent/AU4182000A/en
Priority to CA002365548A priority patent/CA2365548A1/en
Priority to JP2000609558A priority patent/JP2003524400A/en
Publication of WO2000060066A1 publication Critical patent/WO2000060066A1/en
Publication of WO2000060066A8 publication Critical patent/WO2000060066A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The invention provides complexes of at least two polypeptides from the yeast S. cerevisiae and methods of using the same. Purified complexes of two polypeptides are provided, including chimeric complexes, and chimeric polypeptides and complexes thereof are also provided, as are nucleic acids encoding chimeric polypeptides and vectors and cells containing the same. Also provided are methods of identifying agents that disrupt polypeptide complexes, methods of identifying complex or polypeptide in a sample, and for removing the same, methods of determining altered expression of a polypeptide in a subject and methods of treating/preventing disorders involving altered levels of complex or polypeptide.
PCT/US2000/008399 1999-04-01 2000-03-30 Protein-protein from s. cerevisiae and methods of using same WO2000060066A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00921513A EP1165772A1 (en) 1999-04-01 2000-03-30 Protein-protein complexes from s. cerevisiae and methods of using same
AU41820/00A AU4182000A (en) 1999-04-01 2000-03-30 Protein-protein from s. cerevisiae and methods of using same
CA002365548A CA2365548A1 (en) 1999-04-01 2000-03-30 Protein-protein from s. cerevisiae and methods of using same
JP2000609558A JP2003524400A (en) 1999-04-01 2000-03-30 S. Cerevisiae-derived protein-protein and methods of using the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12735299P 1999-04-01 1999-04-01
US60/127,352 1999-04-01
US17896500P 2000-02-01 2000-02-01
US60/178,965 2000-02-01
US09/538,092 US6753314B1 (en) 1999-04-01 2000-03-29 Protein-protein complexes and methods of using same
US09/538,092 2000-03-29

Publications (2)

Publication Number Publication Date
WO2000060066A1 WO2000060066A1 (en) 2000-10-12
WO2000060066A8 true WO2000060066A8 (en) 2001-03-22

Family

ID=27383564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008399 WO2000060066A1 (en) 1999-04-01 2000-03-30 Protein-protein from s. cerevisiae and methods of using same

Country Status (5)

Country Link
US (1) US6753314B1 (en)
EP (1) EP1165772A1 (en)
JP (1) JP2003524400A (en)
CA (1) CA2365548A1 (en)
WO (1) WO2000060066A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995018B1 (en) * 1999-04-09 2006-02-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H
US7208581B1 (en) * 1999-11-05 2007-04-24 The Burnham Institute TRAF family proteins
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
JP2005503336A (en) * 2001-04-02 2005-02-03 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
WO2002097434A1 (en) * 2001-05-29 2002-12-05 Syddansk Universitet Proteins in diabetes proteome analysis
US20030162221A1 (en) * 2001-09-21 2003-08-28 Gary Bader Yeast proteome analysis
US20040209800A1 (en) * 2001-10-18 2004-10-21 Mushinski J. Frederic Use of mx gtpases in the prognosis and treatment of cancer
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
JP2005528913A (en) * 2002-06-10 2005-09-29 メルク　エンド　カムパニー　インコーポレーテッド Isolated nucleic acid molecules encoding novel centromere-related motor proteins and uses thereof
EP2302039A1 (en) * 2002-06-13 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Virus-like particles comprising HML-2 gag polypeptide
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
CA2501222A1 (en) * 2002-10-04 2004-10-21 Mitsubishi Pharma Corporation Antibody recognizing antigen
WO2005068658A1 (en) * 2004-01-17 2005-07-28 Korea Research Institute Of Bioscience And Biotechnology Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
JP5557982B2 (en) * 2004-03-01 2014-07-23 イミューン ディズィーズ インスティテュート インコーポレイテッド Natural IgM antibodies and inhibitors thereof
AU2005268943B2 (en) * 2004-07-31 2011-04-14 Metanomics Gmbh Preparation of organisms with faster growth and/or higher yield
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7795390B2 (en) * 2005-06-24 2010-09-14 Teijin Pharma Limited Biological substance nesfatin and its related substances and uses thereof
CN101300346B (en) * 2005-06-24 2013-04-24 帝人制药株式会社 Novel biological substance nesfatin and its related substances and uses thereof
CA2606130A1 (en) * 2006-03-01 2007-09-13 Suntory Limited Gene encoding glycogen synthesis initiator and use thereof
CA2651800A1 (en) * 2006-04-24 2007-11-08 Shantha West, Inc. Agrm2 antigen
US20080295196A1 (en) 2006-12-06 2008-11-27 Abad Mark S Genes and uses for plant improvement
EP2467499A1 (en) * 2009-08-21 2012-06-27 Oncotherapy Science, Inc. Cstf2 for target genes of lung cancer therapy and diagnosis
EP2330122A1 (en) 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
WO2011071988A1 (en) * 2009-12-08 2011-06-16 Health Research, Inc. Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant
GB2501143B (en) * 2010-02-12 2014-03-26 Gevo Inc Yeast microorganisms genetically engineered to improve isobutanol biosynthesis
US20140017748A1 (en) * 2010-02-12 2014-01-16 Gevo, Inc. Modified alcohol dehydrogenases for the production of fuels and chemicals
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012135500A1 (en) 2011-03-29 2012-10-04 The General Hospital Corporation Engineered thioredoxin-like fold proteins
CN102286499A (en) * 2011-06-16 2011-12-21 山西农业大学 CDNA of alpaca hair color formation associated cyclin-dependent kinase 5(CDK5-A) gene
JP6196034B2 (en) * 2012-12-20 2017-09-13 ライオン株式会社 Marker peptide for determining hyperglycemia risk and use thereof
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies
CN103756984B (en) * 2014-02-18 2015-10-14 吉林大学 High vigor Selenoperoxidase GPX2 mutant and preparation method thereof
CN105693825A (en) * 2016-04-22 2016-06-22 南通大学 Cancer inhibition polypeptide 127aa and expression vector and application thereof
CN105949305A (en) * 2016-06-30 2016-09-21 南通大学 {0><}0{>Sept2 truncated protamine as well as vector and application thereof
US11578108B2 (en) * 2021-03-24 2023-02-14 Chungbuk National University Industrial-Academic Cooperation Foundation Amphiphysin-I mutant having anti-senescence activity and use thereof
CN116162644B (en) * 2022-07-07 2024-04-05 昆明理工大学 New application of phenylalanine ammonia lyase gene pal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025552A1 (en) 1998-01-06 2002-02-28 Institut Pasteur Screening interactor molecules with whole genome oligonucleotide or polynucleotide arrays
WO2000046406A2 (en) 1999-02-05 2000-08-10 Alphagene, Inc. Arrays for investigating protein protein interactions

Also Published As

Publication number Publication date
US6753314B1 (en) 2004-06-22
WO2000060066A1 (en) 2000-10-12
EP1165772A1 (en) 2002-01-02
CA2365548A1 (en) 2000-10-12
JP2003524400A (en) 2003-08-19

Similar Documents

Publication Publication Date Title
WO2000060066A8 (en) Protein-protein from s. cerevisiae and methods of using same
WO1999036550A3 (en) Human protease molecules
CA2295999A1 (en) Nik proteins, nucleic acids and methods
WO1999057311A3 (en) Novel method for the identification of clones conferring a desired biological property from an expression library
WO2001004264A3 (en) Atherosclerosis-associated genes
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
PL299053A1 (en) Amino acid compound being a nucleic acid, vector, host cell, genomic zyme clone, method of diagnozing the alzheimer disease, method of determining and expressing a nucleic acid sequence
WO2001012662A3 (en) Membrane associated proteins
WO1999024463A3 (en) Signal peptide-containing proteins
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
WO1998021343A8 (en) Genes encoding telomerase proteins
AU6277799A (en) Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2004066958A3 (en) Caspase-9:bir3 domain of xiap complexes and methods of use
WO2000021988A3 (en) Human ankyrin family protein
WO2003068940A3 (en) Complexes and methods of using same
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2001005970A3 (en) Gtp-binding protein associated factors
WO2000052151A3 (en) Human secretory proteins
WO1999033870A3 (en) Human regulatory proteins
WO1999058558A3 (en) Cell signaling proteins
WO2001007471A3 (en) Cell cycle and proliferation proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 41/2000 UNDER (30) REPLACE THE EXISTING TEXT BY "60/127352, 01.04.99, US 60/178965, 01.02.2000, US 09/538092, 29.03.2000, US"

ENP Entry into the national phase

Ref document number: 2365548

Country of ref document: CA

Ref country code: CA

Ref document number: 2365548

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609558

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921513

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921513

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000921513

Country of ref document: EP